Notice ID: 87ba55689618d34e6cd3077d3f399c88Presolicitation
Human Cortical Glutamatergic Neurons
Archived on September 21, 2018. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 3:00 PM UTC−05:00
- Posted
- August 31, 2018
- Notice type
- Presolicitation
- NAICS
- 325414: Biological Product (except Diagnostic) Manufacturing
Notice details
- PSC
- Q: MEDICAL SERVICES
- Last updated
- Dec 6, 2025
Identifiers
- Solicitation number
- NIHDA201800526
- Notice ID
- 87ba55689618d34e6cd3077d3f399c88
Description
INTRODUCTION PURSUANT TO FAR Subpart 5.2-Synopses of Proposed Contract Actions, THIS IS A PRE-SOLICITATION NOTICE OF A PROPOSED CONTRACT TO ACTION. THIS IS A PRE-SOLICITATION NON-COMPETITIVE NOTICE OF INTENT TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) intends to award a purchase order to BrainXell, Inc. for services to grow human cortical glutamatergic neurons. The rationale for this sole source is BrainXell utilizes a unique, proprietary mixture of growth factors that accelerate the rate of maturation of the neurons into fully mature neurons in less than five (5) days after thawing. NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS code 325414 - Biological Product (except Diagnostic) Manufacturing and the small business size standard 1,250. REGULATORY AUTHORITY The resultant contract will include all applicable provisions and clauses of the Federal acquisition Requlation (FAR) in effect through the Federal Acquisition Circular (FAC) 2005-100, dated August 22, 2018. STATUTORY AUTHORITY This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures, Subpart 13.106-1 (b) (1), Soliciting from a single source. DESCRIPTION OF REQUIREMENT Project Description Title: Human Cortical Glutamatergic Neurons Background: The National Center for Advancing Translational Sciences (NCATS) focuses on getting more treatments to more patients more quickly. Several thousand genetic diseases affect humans, of which only about 500 have any treatment. NCATS is directly addressing this problem by discovering new technologies and other approaches that could greatly accelerate the process of developing and deploying solutions that can be used by all translational researchers. The Therapeutics for Rare and Neglected Diseases (TRND) biology program's mission is to encourage and speed the development of new treatments for diseases with high-unmet medical needs. N-glycanase 1 (NGLY1) deficiency is an ultra rare, multi-system disease characterized by neurological disorders. To study the pathophysiology of this disease and to facilitate therapeutic development, we have generated induced pluripotent stem cells (iPSCs) from NGLY1 patient fibroblasts as a disease model. The iPSCs now need to be differentiated into disease relevant cells types, specifically, cortical glutamatergic neurons. In patient iPSC-derived neurons, we will investigate cellular phenotypes caused by loss of NGLY1 function and aberrant deglycosylation. In a parallel study, once a disease-specific phenotype is identified, we will perform high-throughput screening of NCATS' compound collection to identify lead compounds for drug development. The contractor will grow the stem cells into actual neurons that have the NGLY1 phenotype. BrainXell will send the neurons to TRND for further testing. The contractor shall be responsible for validating the patient-derived induced pluripotent stem cells (iPSCs), producing the neurons, and assessing the quality of the neurons. Project Requirements: The contractor will receive frozen iPSCs, provided by TRND, that were derived from patients with a lysosomal storage disease. The iPSCs TRND is sending out have the disease phenotype. Contractor will thaw and culture the iPSC line to validate its quality. If necessary, contractor will select and expand high-quality sub-colonies within the culture before neural differentiation. Contractor will produce 20 vials of human cortical glutamatergic neurons from the iPSCs lines. Contractor will freeze all cells and ship them along with seeding supplements that only BrainXell manufactures which will make possible for the neurons to grow and survive in a 1536-well plate environment. Shipment will be overnight using a liquid nitrogen vapor shipper to TRND. Other important considerations: Experience in large quantity production of human cortical glutamatergic neurons from iPSCs lines and capability of high repeatability of these iPSC derived neurons. Capability to accelerate the rate of maturation of the neurons into fully mature neurons in less than five (5) days after thawing. Understanding of the project and technical approach. Purpose and Objectives To procure human cortical glutamatergic neurons differentiated from patient-derived iPSCs for the TRND laboratory. Period of Performance The period of performance shall be four (4) months. Contract Type The Government intends to issue a firm fixed price purchase order for this requirement. CLOSING STATEMENT This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice must include sufficient information to establish the interested parties' bona fide capabilities of providing the product or service. The price quote shall include: total price, delivery date after receipt of order, and any other information or factors that may be considered in the award decision. Such factors may include: technical approach, ability to meet or exceed the delivery date/period of performance, and cost/price. In addition the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by 3:00 PM Eastern Time, Thursday, September 6, 2018, and reference number NIHDA201800526. Responses must be submitted electronically to Contract Specialist Mark McNally at mcnallyme@mail.nih.gov. Fax responses will not be accepted. Contracting Office Address: 6001 Executive Blvd Room 3287, MSC 9534 Bethesda, MD 20892-9534 All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Documents
No documents available.
Lifecycle
Solicitation:
NIHDA201800526- Pre-Solicitation
Formal solicitation typically follows within 30–60 days. (estimate)
- Pre-SolicitationCurrentAug 31, 2018
Human Cortical Glutamatergic Neurons
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Egg-Free Influenza Vaccine Solicitation: SPE2DP26R0004 | - | Solicitation | 12/03/2026 |
Influenza Vaccine Solicitation: SPE2DP26R0003 | - | Solicitation | 12/03/2026 |
NOTICE OF INTENT – SOLE-SOURCE ACQUISITION Notice No.: The National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS), intends to award a Firm-Fixed-Price Purchase Order to Creative Biolab Inc. for culture all cells and differentiate them, expand their cell populations to more than 20 million, collect them, verify cell count, and send them back to us. Description of the Requirement The primary objective of this study is to sequence and analyze the 4q35 locus on Chromosome 4 for several years. This locus is a gene-poor and extremely long (>100K) region of DNA that consists of many repetitive sequences which makes sequencing and analysis extremely difficult. To sequence this locus using Nanopore Sequencing technology. To expand the number of samples for our experiment, we looked for a company that can handle numerous cell lines and follow the protocol that we provide. Creative Biolabs is the only company/research institute that has been able to perform differentiation within 3 months and has the ability to follow our protocol with numerous cell lines. Justification for the Proposed Sole-Source Acquisition The Government intends to solicit from a single source pursuant to FAR 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. Only Creative Biolabs was willing to follow our exact protocol and had the logistical capacity to handle the large number of cell lines that we need to analyze, which is vital to research at the National Institute of Environmental Health Sciences. Response Information This notice is not a request for competitive quotations or proposals. However, interested parties that believe they can meet the Government's requirements may submit a capability statement demonstrating their ability to provide the required preventive maintenance and remedial repair services for the specified instrument and meet all applicable technical and operational requirements. The Government will review timely submissions to determine whether another responsible source is capable of satisfying the requirement and whether a competitive acquisition is appropriate. The Government anticipates making an award approximately five (5) calendar days after the closing date of this notice, unless the Government determines that another responsible source can satisfy the requirement. Capability statements must be submitted electronically to verne.griffin@nih.gov no later than 9:00 a.m. EDT on November 13, 2026. Please reference Notice No. 75N98027Q00053 in the subject line of the submission. | - | Pre-Solicitation | 11/12/2026 |
This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Part 12. This announcement constitutes the only solicitation. Proposals are being requested and a separate written solicitation will not be issued. Solicitation number 12639527R0001 is issued as a Request for Proposal (RFP) for the purchase and storage of Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC), conversion of Government owed VAC into usable vaccine, and the direct purchase of finished vaccine. This acquisition is not set-aside for small business concerns. The applicable North American Industry Classification Standard Code is 325414. The small business size standard is 1,250. This acquisition is an unrestricted requirement. All responsible sources may submit a proposal which will be considered by the agency. | - | Combined Synopsis | 11/10/2026 |
SAM.gov SOURCES SOUGHT NOTICE Solicitation Number: 75N98027Q00029 Title: Tau radiotracers for Baltimore Longitudinal Study of Aging Classification Code: 6505 NAICS Code: 325414 Description: Biological Product (except Diagnostic) Manufacturing This is a Small Business Sources Sought Notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Background: The BLSA was initiated in 1958 and is a multi-disciplinary study of physiologic and psychologic aspects of normal aging in community-dwelling men and women. Since 1994, we have been conducting a longitudinal brain imaging study of selected older adults in the BLSA to characterize individual differences in longitudinal brain changes, to investigate the extent to which these brain changes underlie individual differences in cognitive aging, to identify brain changes that may be predictors of cognitive decline and Alzheimer’s disease (AD), and to assess the impact of potential modulators of brain and cognitive aging. More recently, we have been collecting in vivo measures of brain amyloid and tau, the hallmark pathologies of AD, using PET scanning. The purpose of this acquisition is to acquire FDA- approved second generation tau PET imaging radioligand to perform in vivo Positron Emission Tomography (PET) scans to measure brain tau neuropathology in BLSA participants on a combined PET/computed tomography (CT) scanner. Purpose and Objectives: The purpose of this acquisition is to procure Tau radiotracers for the Baltimore Longitudinal Study of Aging. Project requirements: Independently, and not as an agent of the Government, the Contractor shall provide the following Lantheus products: 70 Tau radioligand doses for the base period. Catalog Number [18F]MK-6240. 70 Tau radioligand doses for option period 1. Catalog Number [18F]MK-6240. 70 Tau radioligand doses for option period 2. Catalog Number [18F]MK-6240. Anticipated period of performance: Base Year: November 18, 2026 – November 17, 2027 Option Year 1: November 18, 2027 – November 17, 2028 Option Year 2: November 18, 2028 – November 17, 2029 Requested Response: The intent of this sources sought notice is to define the procurement strategy (e.g. set-aside, sole source, unrestricted) for a solicitation that is intended to be posted soon. Interested contractors are requested to respond by (1) identifying how their proposed product meets or exceeds the project requirements listed above; and (2) providing product literature, white papers, or capability statements that demonstrate their bona fide ability to supply such an item within the time frame described above. In addition, please state your business size status and whether you are the manufacturer or authorized distributor of the item you propose. Please note that NIH is particularly interested in small business sources. If you are a small business, please state the type of small business (small business; HUBZone; service-disabled, veteran-owned; 8(a); veteran-owned; woman-owned; or small disadvantaged businesses) and your size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. The respondent must also provide their DUNS number, organization name, address, point of contact, and size and type of business (e.g., 8(a), HubZone, etc.), pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. The information submitted must be must be in an outline format that addresses each of the elements of the project requirements and in the capability statement /information sought paragraphs stated herein. A cover page and an executive summary may be included but is not required. The response must include the respondents’ technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and e-mail addresses. All responses to this notice must be submitted electronically to the Contracting Officer. Facsimile responses are NOT accepted. The response must be submitted to Kevin Alvarez, Contracting Officer, at e-mail address kevin.alvarez@nih.gov. The response must be received on or before October 27, 2026, 9:00am, Eastern Time. Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published at SAM.gov. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s). | - | Market Research | 10/27/2026 |
Additional Details
Solicitation Number
NIHDA201800526
Archive Date
Sep 21, 2018